Fenethazine

Fenethazine

SCHEMBL144367

CN(C)CCN1c2ccccc2Sc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 1.00
CYP2D6 P10635 8/20 0.81
CYP1A2 P05177 7/20 0.81
HTR1A P08908 6/20 0.81
TP53 P04637 5/20 0.81
CHRM2 P08172 5/20 0.81
ADRA2A P08913 5/20 0.81
CHRM1 P11229 5/20 0.81
DRD1 P21728 5/20 0.81
SLC6A2 P23975 5/20 0.81
SLC6A4 P31645 5/20 0.81
ADRA1A P35348 5/20 0.81
OPRM1 P35372 5/20 0.81
DRD3 P35462 5/20 0.81
KCNH2 Q12809 5/20 0.81
DRD2 P14416 4/20 0.81
CYP2C19 P33261 4/20 0.81
SIGMAR1 Q99720 4/20 0.81
THPO P40225 3/20 0.81
MTOR P42345 3/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenethazine SCHEMBL29394568 1.00 KDM1A (1.00) KDM1ACYP2D6CYP1A2HTR1ATP53
Fenethazine SCHEMBL662746 0.98 KDM1A (0.96) KDM1ACYP2D6CYP1A2HTR1ATP53
Promazine SCHEMBL9052694 0.89 CYP2D6 (1.00) KDM1ACYP2D6CYP1A2HTR1ATP53
Promazine SCHEMBL29392545 0.89 CYP2D6 (1.00) KDM1ACYP2D6CYP1A2HTR1ATP53
Promazine SCHEMBL140489 0.89 CYP2D6 (1.00) KDM1ACYP2D6CYP1A2HTR1ATP53
Promazine SCHEMBL123418 0.88 LMNA (1.00) KDM1ACYP2D6CYP1A2HTR1ATP53
Promazine SCHEMBL29390978 0.88 LMNA (1.00) KDM1ACYP2D6CYP1A2HTR1ATP53
SCHEMBL6865346 0.88 CYP2D6 (0.90) KDM1ACYP2D6CYP1A2HTR1ATP53
Promazine SCHEMBL27429489 0.88 CYP2D6 (0.97) KDM1ACYP2D6CYP1A2HTR1ATP53
Promazine SCHEMBL27425063 0.88 CYP2D6 (0.97) KDM1ACYP2D6CYP1A2HTR1ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 413 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118993872-A Refining process of fendithiino tussah acid 四川吉龙兴瑞药业有限公司 2024-11-22 CN claimed
CN-117535168-A Bacillus megaterium ZLP-21 and application thereof 河北省科学院生物研究所 2024-02-09 CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20110212173-A1 Controlled Release Treatment of Depression e-Therapeutics Ple (GB) 2011-09-01 US claimed
EP-2315585-A1 CONTROLLED RELEASE TREATMENT OF DEPRESSION E-Therapeutics plc (GB) 2011-05-04 EP claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101801361-A Treatment of depression THERAPEUTICS LTD E 2010-08-11 CN claimed
WO-2010004256-A1 CONTROLLED RELEASE TREATMENT OF DEPRESSION E-THERAPEUTICS PLC (GB) 2010-01-14 WO claimed
EP-2014282-A2 Treatment of depression E-Therapeutics plc (GB) 2009-01-14 EP claimed
US-20090005443-A1 Treatment of Depression E-THERAPEUTICS LIMITED (GB) 2009-01-01 US claimed
WO-2009001040-A2 TREATMENT OF DEPRESSION E-THERAPEUTICS PLC (GB) 2008-12-31 WO claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-2005094832-A1 COMPOSITIONS COMPRISING MELOXICAM BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 WO claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-0599943-A1 LEUKOTRIENE RECEPTOR ANTAGONIST-ANTIHISTAMINE COMPLEX ALLERGAN, INC. (US) 1994-06-08 EP claimed
WO-1993003723-A1 LEUKOTRIENE RECEPTOR ANTAGONIST-ANTIHISTAMINE COMPLEX ALLERGAN, INC. (US) 1993-03-04 WO claimed
US-20260134941-A1 BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING IOGENETICS LLC (US) 2026-05-14 US disclosed
EP-4692178-A1 CELLULOSE POWDER AND MOLDED BODY Asahi Kasei Kabushiki Kaisha (JP) 2026-02-11 EP disclosed
US-12374421-B2 Bioinformatic processes for determination of peptide binding IOGENETICS, LLC (US) 2025-07-29 US disclosed
WO-2025121315-A1 CELLULOSE POWDER AND MOLDED BODY 旭化成株式会社 2025-06-12 WO disclosed
CN-118546816-B Bacillus bailii and application thereof 贵州大学 2025-04-11 CN disclosed
CN-119530052-A Brevibacillus laterosporus and application thereof 中国农业科学院蜜蜂研究所 2025-02-28 CN disclosed
CN-119307411-A Bacillus bailii and separation method and application thereof 山东省烟台市农业科学研究院(山东省农业科学院烟台市分院) 2025-01-14 CN disclosed
CN-119307400-A Salt-tolerant bacillus and application thereof 中国农业科学院蜜蜂研究所 2025-01-14 CN disclosed
CN-119220433-A Bacillus pumilus and application thereof 中国农业科学院蜜蜂研究所 2024-12-31 CN disclosed
CN-119144490-A Bacillus amyloliquefaciens and application thereof 中国农业科学院蜜蜂研究所 2024-12-17 CN disclosed
WO-2024204699-A1 CELLULOSE POWDER AND MOLDED BODY 旭化成株式会社 2024-10-03 WO disclosed
CN-118546816-A Bacillus bailii and application thereof 贵州大学 2024-08-27 CN disclosed
CN-118384290-A Hybrid immunoglobulins containing non-peptide linkages 生物分子控股有限责任公司 2024-07-26 CN disclosed
CN-117511760-B Bacillus polymyxa ZLP-61 and application thereof 河北省科学院生物研究所 2024-07-05 CN disclosed
CN-117535169-B Bacillus licheniformis ZLP-81 and application thereof 河北省科学院生物研究所 2024-06-11 CN disclosed
CN-117535169-A Bacillus licheniformis ZLP-81 and application thereof 河北省科学院生物研究所 2024-02-09 CN disclosed
CN-117511760-A Bacillus polymyxa ZLP-61 and application thereof 河北省科学院生物研究所 2024-02-06 CN disclosed
CN-115011503-B Bacillus bailii microbial inoculum for biological control of tobacco double black disease and application thereof 陕西嘉益蓝德生物工程有限公司 2024-01-19 CN disclosed
CN-116490778-A Compositions and methods for preventing, inhibiting, disrupting or treating a multi-microbial biofilm 国家儿童医院研究所 2023-07-25 CN disclosed
CN-116217277-A Organic biogas slurry fertilizer and preparation method thereof 南京农丰生物科技有限公司 2023-06-06 CN disclosed
EP-3385306-B1 COMPOSITE PARTICLES INCLUDING CELLULOSE, INORGANIC COMPOUND, AND HYDROXYPROPYL CELLULOSE ASAHI CHEMICAL IND (JP) 2023-01-25 EP disclosed
US-20220313656-A1 NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA Københavns Universitet (DK) 2022-10-06 US disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-10869933-B2 Oligomer-phenothiazine conjugates NEKTAR THERAPEUTICS (US) 2020-12-22 US disclosed
WO-2020216777-A1 NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA Københavns Universitet (DK) 2020-10-29 WO disclosed
EP-1712583-B1 POROUS CELLULOSE AGGREGATE AND FORMED PRODUCT COMPOSITION COMPRISING THE SAME ASAHI CHEMICAL IND (JP) 2020-09-16 EP disclosed
US-20200197310-A1 Technology for Preparation of Macromolecular Microspheres NEXBIO, INC. 2020-06-25 US disclosed
US-10583086-B2 Technology for preparation of macromolecular microspheres ANSUN BIOPHARMA, INC. (US) 2020-03-10 US disclosed
US-20200038517-A1 OLIGOMER-PHENOTHIAZINE CONJUGATES NEKTAR THERAPEUTICS (US) 2020-02-06 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
CN-110392680-A Substituted azolyl pyrrolidones and azolyl hydantoins and salts thereof and their use as herbicidal active substances 拜耳作物科学股份公司 2019-10-29 CN disclosed
US-10426838-B2 Composite particles including cellulose, inorganic compound, and hydroxypropyl cellulose ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-10-01 US disclosed
EP-2291233-B1 METHOD FOR DRY GRANULATION ATACAMA LABS OY (FI) 2019-09-04 EP disclosed
CN-106458860-B Pesticidal compositions and methods related thereto 美国陶氏益农公司 2019-07-26 CN disclosed
CN-106165684-B Pesticidal compositions and methods relating thereto 陶氏益农公司 2019-06-14 CN disclosed
US-10265272-B2 Method and apparatus for dry granulation ATACAMA LABS OY (FI) 2019-04-23 US disclosed
US-10231938-B2 Transdermal drug delivery device including an occlusive backing NOVEN PHARMACEUTICALS, INC. (US) 2019-03-19 US disclosed
EP-2254558-B1 ORALLY DISINTEGRATING TABLETS WITH SPECKLED APPEARANCE ALPEX PHARMA SA (CH) 2019-03-13 EP disclosed
CN-105732580-B Pesticidal compositions and methods related thereto 陶氏益农公司 2018-12-07 CN disclosed
CN-105025715-B Pesticidal compositions and methods related thereto 美国陶氏益农公司 2018-11-16 CN disclosed
US-20180326063-A1 COMPOSITE PARTICLES INCLUDING CELLULOSE, INORGANIC COMPOUND, AND HYDROXYPROPYL CELLULOSE ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-11-15 US disclosed
CN-108739826-A Rice shoot field herbicidal and preparation method thereof 芜湖福民生物药业股份有限公司 2018-11-06 CN disclosed
EP-2081669-B1 PROCESS AND APPARATUS FOR FOR PRODUCING GRANULES ATACAMA LABS OY (FI) 2018-10-17 EP disclosed
EP-3385306-A1 COMPOSITE PARTICLES INCLUDING CELLULOSE, INORGANIC COMPOUND, AND HYDROXYPROPYL CELLULOSE Asahi Kasei Kabushiki Kaisha (JP) 2018-10-10 EP disclosed
EP-2391386-B1 OLIGOMER-PHENOTHIAZINE CONJUGATES NEKTAR THERAPEUTICS (US) 2018-06-27 EP disclosed
CN-104981160-B Pesticidal compositions and methods related thereto 美国陶氏益农公司 2018-04-20 CN disclosed
US-20180071219-A1 Technology for Preparation of Macromolecular Microspheres NEXBIO, INC. 2018-03-15 US disclosed
US-20180028449-A1 Technology for the Preparation of Microparticles NEXBIO, INC. 2018-02-01 US disclosed
CN-104981154-B Pesticidal compositions and methods related thereto 美国陶氏益农公司 2018-01-26 CN disclosed
EP-2285355-B1 PROCESS FOR PREPARING A HIGH DRUG LOAD TABLET ATACAMA LABS OY (FI) 2018-01-24 EP disclosed
US-20170281470-A1 METHOD AND APPARATUS FOR DRY GRANULATION ATACAMA LABS OY (FI) 2017-10-05 US disclosed
US-9737386-B2 Dosage projectile for remotely treating an animal SMARTVET PTY LTD (AU) 2017-08-22 US disclosed
EP-2285354-B1 PROCESS FOR PREPARING A LOW DRUG LOAD TABLET ATACAMA LABS OY (FI) 2017-07-19 EP disclosed
US-9700513-B2 Method and apparatus for dry granulation ATACAMA LABS OY (FI) 2017-07-11 US disclosed
CN-104378986-B Pesticidal compositions and methods related thereto 陶氏益农公司 2017-05-31 CN disclosed
US-20170079920-A1 Technology for the Preparation of Microparticles NEXBIO, INC. 2017-03-23 US disclosed
CN-106458860-A Pesticidal compositions and methods related thereto 美国陶氏益农公司 2017-02-22 CN disclosed
CN-106455569-A Use of 3-isoxazolidinone compounds as selective herbicides FMC有限公司 2017-02-22 CN disclosed
CN-103826452-B Pesticidal compositions and processes related thereto 陶氏益农公司 2017-02-01 CN disclosed
CN-103281901-B Pesticidal compositions and methods related thereto 陶氏益农公司 2016-12-28 CN disclosed
US-9494572-B2 Method and compositions for treating cancer and related methods ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2016-11-15 US disclosed
CN-106102463-A Low foaming agrochemical composition 科莱恩国际有限公司 2016-11-09 CN disclosed
US-9446137-B2 Composite particles which contain both cellulose and inorganic compound ASAHI KASEI CHEMICALS CORPORATION (JP) 2016-09-20 US disclosed
US-20160235675-A1 Technology for the Preparation of Microparticles NEXBIO, INC. 2016-08-18 US disclosed
EP-1807033-B1 TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING NOVEN PHARMA (US) 2016-07-20 EP disclosed
US-20160128949-A1 TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING NOVEN PHARMACEUTICALS, INC. (US) 2016-05-12 US disclosed
US-20160132631-A1 BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING IOGENETICS, LLC 2016-05-12 US disclosed
US-20160081782-A1 Dosage Projectile for Remotely Treating an Animal SMARTVET PTY LTD (AU) 2016-03-24 US disclosed
EP-2287234-B1 CELLULOSE POWDER HAVING EXCELLENT SEGREGATION PREVENTIVE EFFECT, AND COMPOSITIONS THEREOF ASAHI KASEI CHEMICALS CORP (JP) 2016-03-23 EP disclosed
EP-2994115-A1 DOSAGE PROJECTILE FOR REMOTELY TREATING AN ANIMAL Smartvet Pty Ltd (AU) 2016-03-16 EP disclosed
US-9238001-B2 Delivery system for remote treatment of an animal SMARTVET PTY LTD. (AU) 2016-01-19 US disclosed
US-20160008777-A1 PHARMACEUTICAL COMPOUNDING KIT NOVOTEC CONSULTING, LLC 2016-01-14 US disclosed
WO-2016007617-A2 PHARMACEUTICAL COMPOUNDING KIT NOVOTEC CONSULTING, LLC. (US) 2016-01-14 WO disclosed
EP-2589618-B1 COMPOSITE PARTICLES WHICH CONTAIN BOTH CELLULOSE AND INORGANIC COMPOUND ASAHI KASEI CHEMICALS CORP (JP) 2015-12-30 EP disclosed
US-20150359746-A1 Technology for the Preparation of Microparticles NEXBIO, INC. 2015-12-17 US disclosed
US-20150290134-A1 TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES NEXBIO, INC. 2015-10-15 US disclosed
US-9155712-B2 Transdermal drug delivery device including an occlusive backing NOVEN PHARMACEUTICALS, INC. (US) 2015-10-13 US disclosed
US-9132195-B2 Cellulose powder having excellent segregation preventive effect, and compositions thereof ASAHI KASEI CHEMICALS CORPORATION (JP) 2015-09-15 US disclosed
US-9134297-B2 Method and compositions for treating cancer and related methods ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2015-09-15 US disclosed
US-20150238427-A1 METHOD AND APPARATUS FOR DRY GRANULATION ATACAMA LABS OY (FI) 2015-08-27 US disclosed
US-20150224101-A1 Method and Compositions for Treating Cancer and Related Methods ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2015-08-13 US disclosed
CN-104758253-A Technology for preparation of macromolecular microspheres NEXBIO INC 2015-07-08 CN disclosed
US-20150174255-A1 COMPOSITE PARTICLES WHICH CONTAIN BOTH CELLULOSE AND INORGANIC COMPOUND ASAHI KASEI CHEMICALS CORPORATION (JP) 2015-06-25 US disclosed
US-20150157578-A1 TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING NOVEN PHARMACEUTICALS, INC. (US) 2015-06-11 US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
US-20150093438-A1 Tramadol for Treating Depression E-THERAPEUTICS PLC (GB) 2015-04-02 US disclosed
EP-2846786-A1 TRAMADOL FOR TREATING DEPRESSION e-Therapeutics plc (GB) 2015-03-18 EP disclosed
US-8968788-B2 Granules, tablets and granulation ATACAMA LABS OY (FI) 2015-03-03 US disclosed
US-20150050713-A1 Technology for the Preparation of Microparticles NEXBIO, INC. 2015-02-19 US disclosed
US-8951636-B2 Composite particles which contain both cellulose and inorganic compound ASAHI KASEI CHEMICALS CORPORATION (JP) 2015-02-10 US disclosed
US-8951562-B2 Method and apparatus or dry granulation ATACAMA LABS OY (FI) 2015-02-10 US disclosed
WO-2014200910-A2 BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING IOGENETICS, LLC (US) 2014-12-18 WO disclosed
US-20140341815-A1 DELIVERY SYSTEM FOR REMOTE TREATMENT OF AN ANIMAL SMARTVET PTY LTD. (AU) 2014-11-20 US disclosed
WO-2014179831-A1 DOSAGE PROJECTILE FOR REMOTELY TREATING AN ANIMAL SMARTVET PTY LTD (AU) 2014-11-13 WO disclosed
CN-104119333-A Guanfu alcohol-amine derivatives as well as preparation method and medical use thereof LIU JINGHAN 2014-10-29 CN disclosed
US-8815281-B2 Transdermal drug delivery device including an occlusive backing NOVEN PHARMACEUTICALS, INC. (US) 2014-08-26 US disclosed
US-8802135-B2 Delivery system for remote treatment of an animal SMARTVET PTY LTD. (AU) 2014-08-12 US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 US disclosed
US-20140134150-A1 TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES ANSUN BIOPHARMA, INC. (US) 2014-05-15 US disclosed
CN-103784408-A Technology for the preparation of microparticles ANSUN BIOPHARMA INC 2014-05-14 CN disclosed
EP-2717860-A1 CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION STI Pharma, LLC (US) 2014-04-16 EP disclosed
US-20140099696-A1 Technology for the Preparation of Microparticles ANSUN BIOPHARMA, INC. (US) 2014-04-10 US disclosed
US-8623419-B2 Technology for preparation of macromolecular microspheres ANSUN BIOPHARMA, INC. (US) 2014-01-07 US disclosed
US-8597686-B2 Porous cellulose aggregate and formed product composition comprising the same ASAHI KASEI CHEMICALS CORPORATION (JP) 2013-12-03 US disclosed
US-8591941-B2 Transdermal drug delivery device including an occlusive backing NOVEN PHARMACEUTICALS, INC. (US) 2013-11-26 US disclosed
US-8581134-B2 Method and apparatus for dry granulation ATACAMA LABS OY (FI) 2013-11-12 US disclosed
US-20130296437-A1 Treatment of Depression E-THERAPEUTICS PLC (GB) 2013-11-07 US disclosed
WO-2013164561-A1 TRAMADOL FOR TREATING DEPRESSION E-THERAPEUTICS PLC (GB) 2013-11-07 WO disclosed
CN-103329907-A Preparation method for fenethazine mycin biochemical germicide SHANGHAI NONGLE BIOLOG PRODUCT CO LTD 2013-10-02 CN disclosed
CN-103329907-A Preparation method for fenethazine mycin biochemical germicide SHANGHAI NONGLE BIOLOG PRODUCT CO LTD 2013-10-02 CN disclosed
US-20130216483-A1 DELIVERY SYSTEM FOR REMOTE TREATMENT OF AN ANIMAL SMARTVET PTY LTD. (AU) 2013-08-22 US disclosed
US-20130204238-A1 COMBINATION THERAPY FOLLICA, INC (US) 2013-08-08 US disclosed
US-8454582-B2 Methods and devices for the treatment of ocular conditions SURMODICS, INC. (US) 2013-06-04 US disclosed
US-8440170-B2 Orally disintegrating tablets with speckled appearance ALPEX PHARMA SA (CH) 2013-05-14 US disclosed
EP-2589618-A1 COMPOSITE PARTICLES WHICH CONTAIN BOTH CELLULOSE AND INORGANIC COMPOUND Asahi Kasei Chemicals Corporation (JP) 2013-05-08 EP disclosed
US-20130108872-A1 COMPOSITE PARTICLES WHICH CONTAIN BOTH CELLULOSE AND INORGANIC COMPOUND ASAHI KASEI CHEMICALS CORPORATION (JP) 2013-05-02 US disclosed
US-8425932-B2 Delivery system for remote treatment of an animal SMARTVET PTY LTD. (AU) 2013-04-23 US disclosed
US-8414914-B2 Compositions for mucosal delivery of agents VIRUN, INC. (US) 2013-04-09 US disclosed
CN-101557871-B Granules, tablets and granulation ATACAMA LABS OY 2013-02-13 CN disclosed
EP-2552323-A1 COMBINATION THERAPY Follica, Inc. (US) 2013-02-06 EP disclosed
US-20120322792-A1 Method and Compositions for Treating Cancer and Related Methods MOUNT SINAI SCHOOL OF MEDICINE (US) 2012-12-20 US disclosed
WO-2012170676-A1 CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION STI PHARMA, LLC (US) 2012-12-13 WO disclosed
US-20120308644-A1 Compositions for mucosal delivery of agents ARCHIMEDES LABORATORIES, INC. 2012-12-06 US disclosed
US-20120269881-A9 TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING NOVEN PHARMACEUTICALS, INC. 2012-10-25 US disclosed
CN-102740854-A Loxoprofen-containing pharmaceutical composition KOWA CO 2012-10-17 CN disclosed
CN-101355876-B Composition suitable for ophthalmic administration COMBINATORX INC 2012-09-05 CN disclosed
US-8252749-B2 Methods, kits, and compositions for generating new hair follicles and growing hair FOLLICA, INC. (US) 2012-08-28 US disclosed
US-8252323-B2 Compositions for mucosal delivery of agents VIRUN, INC. (US) 2012-08-28 US disclosed
EP-1768647-B1 COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT VIRUN INC (US) 2012-08-08 EP disclosed
WO-2012097054-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS MOUNT SINAI SCHOOL OF MEDICINE (US) 2012-07-19 WO disclosed
WO-2012096654-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS MOUNT SINAI SCHOOL OF MEDICINE (US) 2012-07-19 WO disclosed
US-20120165762-A1 TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING NOVEN PHARMACEUTICALS, INC. 2012-06-28 US disclosed
US-20120156228-A1 Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair FOLLICA, INC. (US) 2012-06-21 US disclosed
US-20120141590-A1 Technology for the Preparation of Microparticles MALAKHOV MICHAEL (US) 2012-06-07 US disclosed
WO-2012067630-A1 HAIR GROWTH TREATMENT FOLLICA, INC. (US) 2012-05-24 WO disclosed
WO-2012067632-A1 SEQUENTIAL BODY SURFACE TREATMENT FOLLICA, INC. (US) 2012-05-24 WO disclosed
WO-2012067631-A1 BODY SURFACE TREATMENT FOLLICA, INC. (US) 2012-05-24 WO disclosed
US-20120116062-A1 TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES ANSUN BIOPHARMA, INC. 2012-05-10 US disclosed
US-8158152-B2 Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets SCIDOSE LLC (US) 2012-04-17 US disclosed
US-20120058979-A1 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS ZALICUS INC. (US) 2012-03-08 US disclosed
US-20120046279-A1 Oligomer-Phenothiazine Conjugates NEKTAR THERAPEUTICS (US) 2012-02-23 US disclosed
CN-101005828-B Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents VIRUN INC 2012-01-11 CN disclosed
US-8080553-B2 Methods and reagents for the treatment of immunoinflammatory disorders ZALICUS INC. (US) 2011-12-20 US disclosed
US-8052999-B2 Granules, tablets and granulation ATACAMA LABS (FI) 2011-11-08 US disclosed
WO-2011123218-A1 COMBINATION THERAPY FOLLICA, INC. (US) 2011-10-06 WO disclosed
US-20110212173-A1 Controlled Release Treatment of Depression e-Therapeutics Ple (GB) 2011-09-01 US disclosed
US-20110212173-A1 Controlled Release Treatment of Depression e-Therapeutics Ple (GB) 2011-09-01 US disclosed
US-20110159073-A1 METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS DEJUAN EUGENE 2011-06-30 US disclosed
US-20110140298-A1 METHOD AND APPARATUS OR DRY GRANULATION ATACAMA LABS OY (FI) 2011-06-16 US disclosed
US-20110130711-A1 HAIR GROWTH TREATMENT FOLLICA, INC. (US) 2011-06-02 US disclosed
US-20110130748-A1 BODY SURFACE TREATMENT FOLLICA, INC. (US) 2011-06-02 US disclosed
US-20110130706-A1 SEQUENTIAL BODY SURFACE TREATMENT FOLLICA, INC. (US) 2011-06-02 US disclosed
US-20110117184-A1 Compositions for mucosal delivery of agents VIRUN, INC. 2011-05-19 US disclosed
EP-2315585-A1 CONTROLLED RELEASE TREATMENT OF DEPRESSION E-Therapeutics plc (GB) 2011-05-04 EP disclosed
EP-2315585-A1 CONTROLLED RELEASE TREATMENT OF DEPRESSION E-Therapeutics plc (GB) 2011-05-04 EP disclosed
US-20110097384-A1 TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING NOVEN PHARMACEUTICALS, INC. 2011-04-28 US disclosed
US-20110089087-A1 GRANULES, TABLETS AND GRANULATION POLITI GIOVANNI 2011-04-21 US disclosed
WO-2010004256-A8 CONTROLLED RELEASE TREATMENT OF DEPRESSION E-THERAPEUTICS PLC (GB) 2011-03-31 WO disclosed
EP-2301628-A1 Methods and reagents for the treatment of immunoinflammatory disorders Zalicus Inc. (US) 2011-03-30 EP disclosed
US-20110062630-A1 CELLULOSE POWDER HAVING EXCELLENT SEGREGATION PREVENTIVE EFFECT, AND COMPOSITIONS THEREOF ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-03-17 US disclosed
US-7905852-B2 Skin-contacting-adhesive free dressing JENNINGS-SPRING BARBARA 2011-03-15 US disclosed
US-7906140-B2 Compositions for mucosal delivery of agents VIRUN, INC. (US) 2011-03-15 US disclosed
EP-2291233-A1 METHOD AND APPARATUS FOR DRY GRANULATION Atacama Labs Oy (FI) 2011-03-09 EP disclosed
EP-2287234-A1 CELLULOSE POWDER HAVING EXCELLENT SEGREGATION PREVENTIVE EFFECT, AND COMPOSITIONS THEREOF Asahi Kasei Chemicals Corporation (JP) 2011-02-23 EP disclosed
EP-2285354-A2 PROCESS FOR PREPARING A LOW DRUG LOAD TABLET Atacama Labs Oy (FI) 2011-02-23 EP disclosed
EP-2285355-A2 PROCESS FOR PREPARING A HIGH DRUG LOAD TABLET Atacama Labs Oy (FI) 2011-02-23 EP disclosed
EP-2254558-A1 ORALLY DISINTEGRATING TABLETS WITH SPECKLED APPEARANCE Alpex Pharma SA (CH) 2010-12-01 EP disclosed
US-20100298760-A1 METHODS, KITS, AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS PURETECH VENTURES 2010-11-25 US disclosed
US-20100278754-A1 ORALLY DISINTEGRATING TABLETS WITH SPECKLED APPEARANCE ALPEX PHARMA SA (CH) 2010-11-04 US disclosed
US-20100278784-A1 METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS PURETECH VENTURES (US) 2010-11-04 US disclosed
CN-101848704-A Techniques for preparing microparticles NEXBIO INC 2010-09-29 CN disclosed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US disclosed
EP-2218442-A1 Methods, compositions, and kits for the treatment of ophthalmic disorders CombinatoRx, Inc. (US) 2010-08-18 EP disclosed
US-20100203122-A1 Delivery System for Remote Treatment of an Animal SMARTVET PTY LTD. (AU) 2010-08-12 US disclosed
EP-2214770-A1 METHODS, KITS, AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS Puretech Ventures (US) 2010-08-11 EP disclosed
CN-101801361-A Treatment of depression THERAPEUTICS LTD E 2010-08-11 CN disclosed
CN-101801361-A Treatment of depression THERAPEUTICS LTD E 2010-08-11 CN disclosed
WO-2010088340-A1 OLIGOMER-PHENOTHIAZINE CONJUGATES NEKTAR THERAPEUTICS (US) 2010-08-05 WO disclosed
US-20100184861-A1 METHOD AND APPARATUS FOR DRY GRANULATION ATACAMA LABS OY (FI) 2010-07-22 US disclosed
US-20100166874-A1 Technology for Preparation of Macromolecular Microspheres NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-07-01 US disclosed
US-20100120768-A1 METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR LIGHTHOUSE CAPITAL PARTNERS VI, L.P. 2010-05-13 US disclosed
EP-2173327-A2 TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES Nexbio, Inc. (US) 2010-04-14 EP disclosed
US-20100081713-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS CombinatoRx, (Singapore) Pte. Ltd. 2010-04-01 US disclosed
US-20100069323-A1 COMPOSITION FOR APPLICATION TO SKIN OR MUCOSA ROHTO PHARMACEUTICAL CO., LTD. (JP) 2010-03-18 US disclosed
WO-2010024870-A1 SKIN-CONTACTING-ADHESIVE FREE DRESSING JENNINGS-SPRING BARBARA BROOKE (US) 2010-03-04 WO disclosed
EP-2155146-A1 METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS Puretech Ventures (US) 2010-02-24 EP disclosed
WO-2010004256-A1 CONTROLLED RELEASE TREATMENT OF DEPRESSION E-THERAPEUTICS PLC (GB) 2010-01-14 WO disclosed
WO-2010004256-A1 CONTROLLED RELEASE TREATMENT OF DEPRESSION E-THERAPEUTICS PLC (GB) 2010-01-14 WO disclosed
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed
WO-2009135946-A1 METHOD AND APPARATUS FOR DRY GRANULATION ATACAMA LABS OY (FI) 2009-11-12 WO disclosed
WO-2009135950-A2 PROCESS FOR PREPARING A TABLET CONTAINING EXCIPIENTS ATACAMA LABS OY (FI) 2009-11-12 WO disclosed
WO-2009135949-A2 PROCESS FOR PREPARING A VERY HIGH DRUG LOAD TABLET ATACAMA LABS OY (FI) 2009-11-12 WO disclosed
WO-2009135947-A2 PROCESS FOR PREPARING A LOW DRUG LOAD TABLET ATACAMA LABS OY (FI) 2009-11-12 WO disclosed
WO-2009135948-A2 PROCESS FOR PREPARING A HIGH DRUG LOAD TABLET ATACAMA LABS OY (FI) 2009-11-12 WO disclosed
CN-101557871-A Granules, tablets and granulation ATACAMA LABS OY (FI) 2009-10-14 CN disclosed
CN-101534863-A Composition for application to the skin or mucosa ROHTO PHARMA (JP) 2009-09-16 CN disclosed
WO-2009098169-A1 ORALLY DISINTEGRATING TABLETS WITH SPECKLED APPEARANCE ALPEX PHARMA SA (CH) 2009-08-13 WO disclosed
EP-2081669-A2 GRANULES, TABLETS AND GRANULATION Atacama Labs OY (FI) 2009-07-29 EP disclosed
EP-1846448-B1 DIAGNOSIS OF ALLERGIC COMPLAINTS, ATOPIC DISEASES AND/OR AUTO-IMMUNE DISEASES BY THE IDENTIFICATION OF ANTIBODIES AGAINST CD28 IN HUMAN SERUM UNIVERSITAETSKLINIKUM HAMBURG (DE) 2009-07-22 EP disclosed
EP-2077819-A2 METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR Follica, Inc. (US) 2009-07-15 EP disclosed
EP-2070550-A1 Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases Combinatorx, Incorporated (US) 2009-06-17 EP disclosed
WO-2009061349-A1 METHODS, KITS, AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS PURETECH VENTURES (US) 2009-05-14 WO disclosed
US-20090098207-A1 Technology for the Preparation of Microparticles NEXBIO, INC. (US) 2009-04-16 US disclosed
CN-101404980-A Preparation Technology of Macromolecular Microspheres NEXBIO INC (US) 2009-04-08 CN disclosed
WO-2009001040-A3 TREATMENT OF DEPRESSION E THERAPEUTICS PLC (GB) 2009-02-19 WO disclosed
EP-2014282-A3 Treatment of depression E-Therapeutics plc (GB) 2009-02-18 EP disclosed
WO-2009015286-A2 TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES NEXBIO, INC. (US) 2009-01-29 WO disclosed
CN-101355876-A Methods, compositions and kits for treating medical conditions COMBINATORX INC (US) 2009-01-28 CN disclosed
EP-2014282-A2 Treatment of depression E-Therapeutics plc (GB) 2009-01-14 EP disclosed
EP-2014282-A2 Treatment of depression E-Therapeutics plc (GB) 2009-01-14 EP disclosed
EP-1670427-A4 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX INC (US) 2009-01-07 EP disclosed
US-20090005443-A1 Treatment of Depression E-THERAPEUTICS LIMITED (GB) 2009-01-01 US disclosed
US-20090005722-A1 Skin-contacting-adhesive free dressing JENNLNGS-SPRING BARBARA 2009-01-01 US disclosed
US-20090005443-A1 Treatment of Depression E-THERAPEUTICS LIMITED (GB) 2009-01-01 US disclosed
WO-2009001040-A2 TREATMENT OF DEPRESSION E-THERAPEUTICS PLC (GB) 2008-12-31 WO disclosed
WO-2009001040-A2 TREATMENT OF DEPRESSION E-THERAPEUTICS PLC (GB) 2008-12-31 WO disclosed
WO-2008143928-A1 METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS PURETECH VENTURES (US) 2008-11-27 WO disclosed
WO-2008133884-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-11-06 WO disclosed
EP-1981483-A1 TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES Nexbio, Inc. (US) 2008-10-22 EP disclosed
EP-1956906-A2 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS CombinatoRx, Incorporated (US) 2008-08-20 EP disclosed
EP-0705111-B1 AGENT WITH INFLUENCES HYPERACTIVE IMMUNOLOGICAL EFFECTOR CELLS LESKOVAR PETER (DE) 2008-08-20 EP disclosed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP disclosed
US-20080161324-A1 Compositions and methods for treatment of viral diseases EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) 2008-07-03 US disclosed
US-20080124396-A1 Inhibition of Xenoreactive Antibodies MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2008-05-29 US disclosed
US-20080124396-A1 Inhibition of Xenoreactive Antibodies MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2008-05-29 US disclosed
WO-2008056021-A2 GRANULES, TABLETS AND GRANULATION ATACAMA LABS OY (FI) 2008-05-15 WO disclosed
US-20080111269-A1 Granules, tablets and granulation ATACAMA LABS (FI) 2008-05-15 US disclosed
WO-2008052263-A1 DELIVERY SYSTEM FOR REMOTE TREATMENT OF AN ANIMAL VETERINARY ENCAPSULATION BIOSCIENCES PTY LTD (AU) 2008-05-08 WO disclosed
WO-2008042216-A2 METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR FOLLICA, INC. (US) 2008-04-10 WO disclosed
EP-1904031-A2 A SUBSTANTIALLY WATER-FREE PRESSURISED PROPELLANT MIXTURE THERAPICON SRL (IT) 2008-04-02 EP disclosed
WO-2008033466-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PRE. LTD. (SG) 2008-03-20 WO disclosed
US-20080063698-A1 Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use NOVEN PHARMACEUTICALS, INC. 2008-03-13 US disclosed
CN-101102760-A Methods and agents for treating immunoinflammatory disorders COMBINATORX (US) 2008-01-09 CN disclosed
US-20070299043-A1 Anti-scarring drug combinations and use thereof HUNTER WILLIAM L 2007-12-27 US disclosed
EP-1680121-A4 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX INC (US) 2007-12-26 EP disclosed
EP-1846448-A1 DIAGNOSIS OF ALLERGIC COMPLAINTS, ATOPIC DISEASES AND/OR AUTO-IMMUNE DISEASES BY THE IDENTIFICATION OF ANTIBODIES AGAINST CD28 IN HUMAN SERUM Universitätsklinikum Hamburg-Eppendorf (DE) 2007-10-24 EP disclosed
WO-2007114881-A1 TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES NEXBIO, INC. (US) 2007-10-11 WO disclosed
EP-1675550-A4 THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS COMBINATORX INC (US) 2007-10-10 EP disclosed
US-20070225217-A1 Methods, compositions, and kits for the treatment of medical conditions COMBINATORX, INCORPORATED (US) 2007-09-27 US disclosed
US-20070208134-A1 Anti-scarring drug combinations and use thereof HUNTER WILLIAM L 2007-09-06 US disclosed
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof ANGIOTECH INTERNATIONAL AG (CH) 2007-08-23 US disclosed
US-20070198063-A1 Electrical devices and anti-scarring drug combinations HUNTER WILLIAM L 2007-08-23 US disclosed
US-20070197957-A1 Implantable sensors, implantable pumps and anti-scarring drug combinations HUNTER WILLIAM L 2007-08-23 US disclosed
US-20070190163-A1 Technology for preparation of macromolecular microspheres THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTE OF HEALTH 2007-08-16 US disclosed
US-20070190017-A1 Porous cellulose aggregate and formed product composition comprising the same ASAHI KASEI CHEMICALS CORPORATION (JP) 2007-08-16 US disclosed
CN-101005828-A Compositions comprising a mucoadhesive protein and an activeprinciple for mucosal delivery of said agents VIRUN INC (US) 2007-07-25 CN disclosed
EP-1807033-A2 TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING NOVEN PHARMACEUTICALS, INC. (US) 2007-07-18 EP disclosed
CN-1993051-A Treatment regimens for combination administration COMBINATORX INC (US) 2007-07-04 CN disclosed
EP-1796661-A2 LARGE-SCALE MANUFACTURING PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS Naryx Pharma, Inc. (US) 2007-06-20 EP disclosed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO disclosed
WO-2007041677-A9 SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF COMBINATORX INC (US) 2007-05-31 WO disclosed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US disclosed
EP-0665289-B1 Peptides from GAD65, provoking autoimmune reactions ROCHE DIAGNOSTICS GMBH (DE) 2007-05-23 EP disclosed
WO-2007056457-A2 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS COMBINATORX, INCORPORATED (US) 2007-05-18 WO disclosed
WO-2007041593-A2 ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed
WO-2007041584-A2 IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed
WO-2007041463-A2 ELECTRICAL DEVICES AND ANTI-SCARRING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed
WO-2007041677-A2 SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed
EP-1768647-A1 COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT Virun, Inc. (US) 2007-04-04 EP disclosed
CN-1902488-A Screening assays and methods of tumor treatment GENENTECH INC (US) 2007-01-24 CN disclosed
US-20070010502-A1 Methods and reagents for the treatment of immunoinflammatory disorders COMBINATORX INC. (US) 2007-01-11 US disclosed
CN-1889956-A Methods and reagents for the treatment of immunoinflammatory disorders COMBINATORX INC (US) 2007-01-03 CN disclosed
WO-2006122905-A2 A SUBSTANTIALLY WATER-FREE PRESSURISED PROPELLANT MIXTURE THERAPICON SRL (IT) 2006-11-23 WO disclosed
EP-1712583-A1 POROUS CELLULOSE AGGREGATE AND FORMED PRODUCT COMPOSITION COMPRISING THE SAME Asahi Kasei Chemicals Corporation (JP) 2006-10-18 EP disclosed
US-7122198-B1 Fast dissolving composition with prolonged sweet taste PANACEA BIOTEC LIMITED (IN) 2006-10-17 US disclosed
WO-2006082066-A1 DIAGNOSIS OF ALLERGIC COMPLAINTS, ATOPIC DISEASES AND/OR AUTO-IMMUNE DISEASES BY THE IDENTIFICATION OF ANTIBODIES AGAINST CD28 IN HUMAN SERUM Universitätsklinikum Hamburg-Eppendorf (DE) 2006-08-10 WO disclosed
EP-1680121-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS CombinatoRx, Incorporated (US) 2006-07-19 EP disclosed
EP-1675550-A2 THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS CombinatoRx, Incorporated (US) 2006-07-05 EP disclosed
EP-1670427-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS CombinatoRx, Incorporated (US) 2006-06-21 EP disclosed
US-20060110428-A1 Methods and devices for the treatment of ocular conditions SURMODICS MD, LLC 2006-05-25 US disclosed
US-20060099256-A1 Microspheres and related processes and pharmaceutical compositions PRICE JAMES C 2006-05-11 US disclosed
WO-2006044206-A2 TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING NOVEN PHARMACEUTICALS, INC. (US) 2006-04-27 WO disclosed
WO-2006041592-A2 LARGE-SCALE MANUFACTURING PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS NARYX PHARMA, INC. (US) 2006-04-20 WO disclosed
CN-1761478-A Combination therapy for the treatment of immunoinflammatory disorders COMBINATORX INC (US) 2006-04-19 CN disclosed
US-20060078604-A1 Transdermal drug delivery device including an occlusive backing NOVEN PHARMACEUTICALS, INC. 2006-04-13 US disclosed
EP-1644487-A1 REGULATORY T-CELLS CONTAINING GALECTINS FOR THE THERAPY AND DIAGNOSIS OF DISEASES Protagen AG (DE) 2006-04-12 EP disclosed
US-20060073173-A1 Large-scale manufacturing process for the production of pharmaceutical compositions NARYX PHARMA, INC. 2006-04-06 US disclosed
US-7001892-B1 Pharmaceutical materials and methods for their preparation and use PURDUE RESEARCH FOUNDATION (US) 2006-02-21 US disclosed
WO-2006014484-A2 METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS SURMODICS, INC. (US) 2006-02-09 WO disclosed
EP-1599212-A4 COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX INC (US) 2006-02-08 EP disclosed
WO-2006009825-A1 COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENTS VIRUN, INC. (US) 2006-01-26 WO disclosed
WO-2006001815-A1 ACTIVE AGENTS USING LIPOSOME MACRO-BEADS SUVANPRAKORN PICHIT (TH) 2006-01-05 WO disclosed
EP-1021204-B1 BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS NOVEN PHARMA (US) 2005-12-28 EP disclosed
US-20050281772-A1 Compositions for mucosal delivery of agents VIRUN, INC. 2005-12-22 US disclosed
EP-1599212-A2 COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS Combinatorx, Incorporated (US) 2005-11-30 EP disclosed
WO-2005094832-A1 COMPOSITIONS COMPRISING MELOXICAM BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 WO disclosed
EP-1087791-B1 INHIBITION OF XENOREACTIVE ANTIBODIES MAYO FOUNDATION (US) 2005-09-21 EP disclosed
EP-1087791-B1 INHIBITION OF XENOREACTIVE ANTIBODIES MAYO FOUNDATION (US) 2005-09-21 EP disclosed
US-20050192261-A1 Methods and reagents for the treatment of immunoinflammatory disorders COMBINATORX INCORPORATED 2005-09-01 US disclosed
US-20050166269-A1 Sleep genes in Drosophila and their use for the screening, diagnosis and therapy of sleep disorders WISCONSIN ALUMNI RESEARCH FOUNDATION 2005-07-28 US disclosed
WO-2005061736-A2 SLEEP GENES IN DROSOPHILA AND THEIR USE FOR THE SCREENING, DIAGNOSIS AND THERAPY OF SLEEP DISORDERS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2005-07-07 WO disclosed
US-20050119160-A1 Methods and reagents for the treatment of immunoinflammatory disorders ZALICUS INC. 2005-06-02 US disclosed
US-20050112199-A1 Therapeutic regimens for administering drug combinations COMBINATORX, INCORPORATED 2005-05-26 US disclosed
CN-1202261-C Methods for making recombinant cells SUNOL MOLECULAR CORP (US) 2005-05-18 CN disclosed
WO-2005037203-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2005-04-28 WO disclosed
WO-2005030132-A2 THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2005-04-07 WO disclosed
WO-2005027839-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2005-03-31 WO disclosed
CN-1582142-A Ibuprofen salt emulsifiers and cream formulations containing same MACROCHEM CORP (US) 2005-02-16 CN disclosed
US-20050032900-A1 Ibuprofen salt emulsifiers and cream formulations containing same MACROCHEM CORPORATION 2005-02-10 US disclosed
WO-2005007836-A1 REGULATORY T-CELLS CONTAINING GALECTINS FOR THE THERAPY AND DIAGNOSIS OF DISEASES PROTAGEN AG (DE) 2005-01-27 WO disclosed
US-20050002865-A1 Diagnostic/therapeutic agents AMERSHAM HEALTH AS (NO) 2005-01-06 US disclosed
US-20040224012-A1 Topical application and methods for administration of active agents using liposome macro-beads BIOPHILE CORPORATION LTD. (TH) 2004-11-11 US disclosed
US-20040224876-A1 Combination therapy for the treatment of immunoinflammatory disorders COMBINATORX, INCORPORATED 2004-11-11 US disclosed
EP-1137808-B1 METHODS FOR MAKING RECOMBINANT CELLS SUNOL MOLECULAR CORP (US) 2004-09-29 EP disclosed
WO-2004073614-A2 COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2004-09-02 WO disclosed
US-20040156859-A1 GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups CONJUCHEM, INC. (CA) 2004-08-12 US disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 US disclosed
US-20040141944-A1 Inhibition of xenoreactive antibodies BIOSCIENCE 2002 LLC 2004-07-22 US disclosed
US-20040141944-A1 Inhibition of xenoreactive antibodies BIOSCIENCE 2002 LLC 2004-07-22 US disclosed
US-20040142023-A1 Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use NOVEN PHARMACEUTICALS, INC. 2004-07-22 US disclosed
EP-1432405-A1 IBUPROFEN SALT EMULSIFIERS AND CREAM FORMULATIONS CONTAINING SAME MacroChem Corporation (US) 2004-06-30 EP disclosed
WO-2004050066-A1 MICROSPHERES AND RELATED PROCESSES AND PHARMACEUTICAL COMPOSITIONS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2004-06-17 WO disclosed
US-20040115258-A1 Oral pharmaceutical compositions containing cyclodextrins as taste masking agent ELAN PHARMA SA (CH) 2004-06-17 US disclosed
US-6706892-B1 ADMINSTERING MALEIMIDE DERIVATIVE TO COVALENTLY BOND PROTEIN; WOUND HEALING, ANTIBIOTIC, ANTIINFLAMMATORY, ANTICARCINOGENIC, HYPOTENSIVE, AND ANALGESIC AGENTS CONJUCHEM, INC. (CA) 2004-03-16 US disclosed
US-20040018241-A1 Bioadhesive compositions and methods for topical administration of active agents NOVEN PHARMACEUTICALS, INC. 2004-01-29 US disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 US disclosed
US-6638528-B1 Pressure-sensitive adhesive matrix comprising blend of polyacrylate, polysiloxane, polyisobutylene, polyisoprene, polyamide or polystyrene; and insoluble, non-adhesive ethyl cellulose; polyvinylpyrrolidone crystallization inhibitor NOVEN PHARMACEUTICALS, INC. 2003-10-28 US disclosed
EP-1347781-A1 ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLODEXTRINS AS TASTE MASKING AGENT ELAN CORPORATION, Plc (IE) 2003-10-01 EP disclosed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP disclosed
US-20030152616-A1 Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use NOVEN PHARMACEUTICALS, INC. 2003-08-14 US disclosed
US-6572867-B1 Reducing plasma levels of anti-( alpha Gal(1,3)Gal) antibodies; nonimmunogenic polymers comprise alpha Gal(1,3) Gal moieties covalently linked to said polymer; cross-links are covalent tethers, derived from N-hydroxysulfosuccinimide BAXTER INTERNATIONAL INC. 2003-06-03 US disclosed
US-6572867-B1 Reducing plasma levels of anti-( alpha Gal(1,3)Gal) antibodies; nonimmunogenic polymers comprise alpha Gal(1,3) Gal moieties covalently linked to said polymer; cross-links are covalent tethers, derived from N-hydroxysulfosuccinimide BAXTER INTERNATIONAL INC. 2003-06-03 US disclosed
EP-1310247-A1 (+)-ephedrine as a sympathomimetic drug Warner-Lambert Company LLC (US) 2003-05-14 EP disclosed
EP-1030659-B1 Pharmaceutical composition comprising (+)-EPHEDRINE and an H1 receptor antagonist WARNER LAMBERT CO (US) 2003-05-14 EP disclosed
US-6562363-B1 Bioadhesive compositions and methods for topical administration of active agents NOVEN PHARMACEUTICALS, INC. 2003-05-13 US disclosed
WO-2003030818-A2 ACTIVE AGENTS USING LIPOSOME BEADS SUVANPRAKORN PICHIT (TH) 2003-04-17 WO disclosed
US-20030068365-A1 Compositions and methods for administration of active agents using liposome beads BIOPHILE CORPORATION, LTD. (TH) 2003-04-10 US disclosed
WO-2003028702-A1 IBUPROFEN SALT EMULSIFIERS AND CREAM FORMULATIONS CONTAINING SAME MACROCHEM CORPORATION (US) 2003-04-10 WO disclosed
JP-2003012514-A MEDICAMENT COMPOSITION TAISHO PHARMACEUT CO LTD 2003-01-15 JP disclosed
CN-1092925-C Metribuzin-amide herbicide composition and preparation thereof INST OF PLANT AND ENVIRONMENT (CN) 2002-10-23 CN disclosed
US-6465004-B1 ESTERIFIED OR ACYLATED CELLULOSE TO STABILIZE THE CONCENTRATION OF THE ACTIVE AGENT IN THE COMPOSITION AND TO INHIBIT CRYSTAL FORMATION; PRESSURE-SENSITIVE ADHESIVE CARRIER; CELLULOSE ACETATE BUTYRATE NOVEN PHARMACEUTICALS, INC. 2002-10-15 US disclosed
EP-1137808-A4 METHODS FOR MAKING RECOMBINANT CELLS SUNOL MOLECULAR CORP (US) 2002-10-02 EP disclosed
EP-1235561-A2 FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE Panacea Biotec Limited (IN) 2002-09-04 EP disclosed
EP-1235618-A2 BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS Conjuchem, Inc. (CA) 2002-09-04 EP disclosed
US-20020106402-A1 Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use NOVEN PHARMACEUTICALS, INC. 2002-08-08 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
EP-1223216-A1 Intracellular nucleic acid inhibitors of small guanine-nucleotide-exchange factors NascaCell GmbH (DE) 2002-07-17 EP disclosed
WO-2002053731-A1 INTRACELLULAR NUCLEIC ACID INHIBITORS OF SMALL GUANINE NUCLEOTIDE EXCHANGE FACTORS NASCACELL GMBH (DE) 2002-07-11 WO disclosed
WO-2000076480-A9 PHARMACEUTICAL MATERIALS AND METHODS FOR THEIR PREPARATION AND USE LILLY CO ELI (US) 2002-07-11 WO disclosed
WO-2002045701-A2 CRYSTALLIZATION INHIBITION OF DRUGS IN TRANSDERMAL DRUG DELIVERY SYSTEMS NOVEN PHARMACEUTICALS, INC. (US) 2002-06-13 WO disclosed
WO-2002041920-A1 ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLODEXTRINS AS TASTE MASKING AGENT ELAN CORPORATION, PLC (US) 2002-05-30 WO disclosed
EP-1189599-A2 PHARMACEUTICAL MATERIALS AND METHODS FOR THEIR PREPARATION AND USE ELI LILLY AND COMPANY (US) 2002-03-27 EP disclosed
US-20020004065-A1 Compositions and methods to effect the release profile in the transdermal administration of active agents KANIOS DAVID (US) 2002-01-10 US disclosed
CN-1328605-A Method for producing recombinant cell SUNOL MOLECULAR CORP (US) 2001-12-26 CN disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
WO-2001091799-A2 MEDICAMENT FOR THE TREATMENT OF IMMUNE REACTIONS IN THE EYE MOLOGEN FORSCHUNGS-, ENTWICKLUNGS- UND VERTRIEBS GMBH (DE) 2001-12-06 WO disclosed
US-6306605-B1 HIGH LEVEL EXPRESSION OF AN AMINO ACID SEQUENCE BY INTRODUCING VECTORS OF SELECTABLE SEQUENCES LINKED TO SEGMENT ENCODING AT LEAST ONE COPY OF AMINO ACID SEQUENCE, CULTURING TO SELECT VECTORS, ISOLATING CELLS EXPRESSING THE SEQUENCE SUNOL MOLECULAR CORPORATION 2001-10-23 US disclosed
EP-1137808-A1 METHODS FOR MAKING RECOMBINANT CELLS Sunol Molecular Corporation (US) 2001-10-04 EP disclosed
WO-2001052823-A2 COMPOSITIONS TO EFFECT THE RELEASE PROFILE IN THE TRANSDERMAL ADMINISTRATION OF DRUGS NOVEN PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
CN-1302544-A Metribuzin-amide herbicide composition and preparation thereof INST OF PLANT AND ENVIRONMENT (CN) 2001-07-11 CN disclosed
WO-2001039749-A2 FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE PANACEA BIOTEC LIMITED (IN) 2001-06-07 WO disclosed
US-6221383-B1 BLEND OF AT LEAST TWO POLYMERS, OR AT LEAST ONE POLYMER AND A SOLUBLE POLYVINYLPYRROLIDONE, IN COMBINATION WITH A DRUG PROVIDES A PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR A TRANSDERMAL DRUG DELIVERY SYSTEM NOVEN PHARMACEUTICALS, INC. 2001-04-24 US disclosed
EP-1087791-A1 INHIBITION OF XENOREACTIVE ANTIBODIES Baxter International Inc. (US) 2001-04-04 EP disclosed
EP-1087791-A1 INHIBITION OF XENOREACTIVE ANTIBODIES Baxter International Inc. (US) 2001-04-04 EP disclosed
US-6207389-B1 PROTEIN FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DIABETES HRC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2001-03-27 US disclosed
WO-2001017568-A2 BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS CONJUCHEM, INC. (CA) 2001-03-15 WO disclosed
CN-1060912-C Metribuzin and amide herbicide composition and preparation thereof INST OF PLANT PROT AND ENVIRON (CN) 2001-01-24 CN disclosed
WO-2000076480-A2 PHARMACEUTICAL MATERIALS AND METHODS FOR THEIR PREPARATION AND USE ELI LILLY AND COMPANY (US) 2000-12-21 WO disclosed
WO-2000074661-A2 SOLUBILITY ENHANCEMENT OF DRUGS IN TRANSDERMAL DRUG DELIVERY SYSTEMS AND METHODS OF USE NOVEN PHARMACEUTICALS, INC. (US) 2000-12-14 WO disclosed
US-6156514-A PREPARING AGGREGATES WITH AMPLIFIED AMINO ACID SEQUENCE EXPRESSION; TRANSFORM TISSUE, CULTURE TISSUE, ISOLATE TISSUE EXPRESSING AMINO ACID SEQUENCES, TRANSFORM AND CULTURE TISSUE, ISOLATE TISSUE WHICH EXPRESSES AMINO ACID SEQUENCES SUNOL MOLECULAR CORPORATION (US) 2000-12-05 US disclosed
EP-1030659-A1 (+)-EPHEDRINE AS A SYMPATHOMIMETIC DRUG WARNER-LAMBERT COMPANY (US) 2000-08-30 EP disclosed
EP-1021204-A2 BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS NOVEN PHARMACEUTICALS, INC. (US) 2000-07-26 EP disclosed
WO-2000032821-A1 METHODS FOR MAKING RECOMBINANT CELLS SUNOL MOLECULAR CORPORATION (US) 2000-06-08 WO disclosed
US-6024976-A TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH NOVEN PHARMACEUTICALS, INC. (US) 2000-02-15 US disclosed
WO-1999052561-A1 INHIBITION OF XENOREACTIVE ANTIBODIES BAXTER INTERNATIONAL INC. (US) 1999-10-21 WO disclosed
WO-1999052561-A1 INHIBITION OF XENOREACTIVE ANTIBODIES BAXTER INTERNATIONAL INC. (US) 1999-10-21 WO disclosed
WO-1999025328-A1 (+)-EPHEDRINE AS A SYMPATHOMIMETIC DRUG WARNER-LAMBERT COMPANY (US) 1999-05-27 WO disclosed
EP-0910410-A1 TOPICAL COMPOSITION COMPRISING A COMBINATION OF ANTIHISTAMINIC COMPOUNDS WITH TERPENOID COMPOUNDS Novartis Consumer Health S.A. (CH) 1999-04-28 EP disclosed
WO-1999015210-A2 BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS NOVEN PHARMACEUTICALS, INC. (US) 1999-04-01 WO disclosed
US-5883229-A BCL-Y IS INVOLVED IN MEDIATING CELL DEATH OR SURVIVAL COCENSYS, INC. (US) 1999-03-16 US disclosed
US-5789201-A CONTROLLING APOPTOSIS; MAMMALS COCENSYS, INC. (US) 1998-08-04 US disclosed
US-5763585-A MODULATORS OF T-CELLS FOR IMMUNOLOGICAL DISORDERS ANERGEN, INC. (US) 1998-06-09 US disclosed
EP-0839191-A1 AUTOREACTIVE PEPTIDES FROM HUMAN GLUTAMIC ACID-DECARBOXYLASE (GAD) Roche Diagnostics GmbH (DE) 1998-05-06 EP disclosed
EP-0833930-A2 FUSED SOLUBLE MHC HETERODIMER:PEPTIDE COMPLEXES AND THEIR USES ZymoGenetics, Inc. (US) 1998-04-08 EP disclosed
US-5719197-A DRUG DELIVERY NOVEN PHARMACEUTICALS, INC. (US) 1998-02-17 US disclosed
WO-1998001134-A1 ORAL PHARMACEUTICAL COMBINATIONS OF ANTIHISTAMINIC COMPOUNDS AND TERPENOIDS NOVARTIS CONSUMER HEALTH S.A. (CH) 1998-01-15 WO disclosed
WO-1998000168-A1 TOPICAL COMPOSITION COMPRISING A COMBINATION OF ANTIHISTAMINIC COMPOUNDS WITH TERPENOID COMPOUNDS NOVARTIS CONSUMER HEALTH S.A. (CH) 1998-01-08 WO disclosed
CN-1148465-A Metribuzin and amide herbicide composition and preparation thereof INST OF PLANT PROTECTION AND E (CN) 1997-04-30 CN disclosed
EP-0759035-A1 METHODS FOR CONTROLLING T LYMPHOCYTE MEDIATED IMMUNE RESPONSES HSC Research and Development Limited Partnership (CA) 1997-02-26 EP disclosed
WO-1997004085-A1 AUTOREACTIVE PEPTIDES FROM HUMAN GLUTAMIC ACID-DECARBOXYLASE (GAD) BOEHRINGER MANNHEIM GMBH (DE) 1997-02-06 WO disclosed
WO-1996040084-A1 COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT NOVEN PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
WO-1996040086-A2 COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS NOVEN PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
WO-1996040944-A2 FUSED SOLUBLE MHC HETERODIMER:PEPTIDE COMPLEXES AND THEIR USES ZYMOGENETICS, INC. (US) 1996-12-19 WO disclosed
EP-0705111-A1 AGENT WITH INFLUENCES HYPERACTIVE IMMUNOLOGICAL EFFECTOR CELLS LESKOVAR, Peter (DE) 1996-04-10 EP disclosed
WO-1995029936-A1 METHODS FOR CONTROLLING T LYMPHOCYTE MEDIATED IMMUNE RESPONSES HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 1995-11-09 WO disclosed
US-5446070-A Flexible, finite, bioadhesive, therapeutical agent in solid form NOVER PHARMACEUTICALS, INC. (US) 1995-08-29 US disclosed
EP-0665289-A2 Peptides from GAD65, provoking autoimmune reactions Roche Diagnostics GmbH (DE) 1995-08-02 EP disclosed
WO-1995000175-A1 AGENT WITH INFLUENCES HYPERACTIVE IMMUNOLOGICAL EFFECTOR CELLS LESKOVAR PETER (DE) 1995-01-05 WO disclosed
US-5276044-A For topical application having enhanced effectiveness and decreased irritancy ALLERGAN, INC. (US) 1994-01-04 US disclosed
EP-0537143-A1 COMPOSITION AND PROCESS FOR TREATING WATER CONTAINING METAL IONS AND ORGANIC AND/OR INORGANIC IMPURITIES. STRATEN GUENTER (DE) 1993-04-21 EP disclosed
EP-0537143-A1 COMPOSITION AND PROCESS FOR TREATING WATER CONTAINING METAL IONS AND ORGANIC AND/OR INORGANIC IMPURITIES. STRATEN GUENTER (DE) 1993-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (26 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 KDM1A 4361/4885CYP2D6 4840/4885CYP1A2 4874/4885
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES HTR1A, HTR3B, HTR3A KDM1A 491/4885CYP2D6 650/4885CYP1A2 588/4885
US-20070010502-A1 Methods and reagents for the treatment of immunoinflammatory disorders IL5, TPMT, TSLP KDM1A 3260/4885CYP2D6 981/4885CYP1A2 1083/4885
US-20040141944-A1 Inhibition of xenoreactive antibodies LY96, CD47, HLA-A KDM1A 2177/4885CYP2D6 2168/4885CYP1A2 2145/4885
US-20050002865-A1 Diagnostic/therapeutic agents FUS, HNRNPF, HNRNPR KDM1A 4843/4885CYP2D6 4709/4885CYP1A2 4806/4885
US-20070225217-A1 Methods, compositions, and kits for the treatment of medical conditions TNF, PYGM, IL6 KDM1A 4174/4885CYP2D6 3055/4885CYP1A2 2802/4885
US-20220313656-A1 NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA NR4A1, NR4A3, NR1H4 KDM1A 4059/4885CYP2D6 201/4885CYP1A2 197/4885
US-20080124396-A1 Inhibition of Xenoreactive Antibodies LY96, HLA-A, CD47 KDM1A 1843/4885CYP2D6 1854/4885CYP1A2 1804/4885
US-20080161324-A1 Compositions and methods for treatment of viral diseases HAVCR2, EIF2AK2, RNASE1 KDM1A 1320/4885CYP2D6 1538/4885CYP1A2 1154/4885
US-10869933-B2 Oligomer-phenothiazine conjugates HTT, MAPT, SLCO1B3 KDM1A 4268/4885CYP2D6 283/4885CYP1A2 377/4885
US-20260134941-A1 BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING MICA, HLA-DRB1, CD74 KDM1A 4790/4885CYP2D6 3040/4885CYP1A2 4831/4885
US-20040156859-A1 GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups OGFR, HDGF, SERPINA6 KDM1A 2836/4885CYP2D6 1094/4885CYP1A2 2699/4885
US-20070208134-A1 Anti-scarring drug combinations and use thereof MMP1, COL2A1, COL1A1 KDM1A 1259/4885CYP2D6 3701/4885CYP1A2 1939/4885
US-20050192261-A1 Methods and reagents for the treatment of immunoinflammatory disorders IL5, CMA1, CCL11 KDM1A 1594/4885CYP2D6 835/4885CYP1A2 668/4885
US-20040224876-A1 Combination therapy for the treatment of immunoinflammatory disorders HLA-DRB1, TSLP, SERPINA6 KDM1A 4496/4885CYP2D6 501/4885CYP1A2 773/4885
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof COL2A1, MMP1, FN1 KDM1A 1466/4885CYP2D6 597/4885CYP1A2 869/4885
US-20070299043-A1 Anti-scarring drug combinations and use thereof MMP1, COL2A1, COL1A1 KDM1A 1259/4885CYP2D6 3701/4885CYP1A2 1939/4885
US-20100120768-A1 METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR NGF, HDGF, SHH KDM1A 2646/4885CYP2D6 4169/4885CYP1A2 3033/4885
US-20200038517-A1 OLIGOMER-PHENOTHIAZINE CONJUGATES HTT, MAPT, SLCO1B3 KDM1A 4268/4885CYP2D6 283/4885CYP1A2 377/4885
US-20120156228-A1 Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair NGF, HDGF, SHH KDM1A 2646/4885CYP2D6 4169/4885CYP1A2 3033/4885
US-20120046279-A1 Oligomer-Phenothiazine Conjugates HTT, MAPT, SLCO1B3 KDM1A 4268/4885CYP2D6 283/4885CYP1A2 377/4885
US-20100081713-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS IFNG, IL5, HAVCR2 KDM1A 1579/4885CYP2D6 4016/4885CYP1A2 2396/4885
US-20120058979-A1 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS IL5, TPMT, TSLP KDM1A 3260/4885CYP2D6 981/4885CYP1A2 1083/4885
US-20050032900-A1 Ibuprofen salt emulsifiers and cream formulations containing same ALOX12, NAPEPLD, ACMSD KDM1A 2080/4885CYP2D6 229/4885CYP1A2 312/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 KDM1A 4293/4885CYP2D6 4855/4885CYP1A2 4880/4885
US-20050119160-A1 Methods and reagents for the treatment of immunoinflammatory disorders IL5, TPMT, TSLP KDM1A 3260/4885CYP2D6 981/4885CYP1A2 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.